ABSTRACT
Objective@#To explore the improvement rate of liver fibrosis in patients with chronic hepatitis B virus infection who received entecavir alone or in combination with anluohuaxianwan for 78 weeks.@*Methods@#Patients with chronic HBV infection were randomly treated with entecavir alone or in combination with anluohuaxian for 78 weeks. Ishak fibrosis score was used for blind interpretation of liver biopsy specimens. The improvement in liver fibrosis condition before and after the treatment was compared. Student's t test and non-parametric test (Mann-Whitney U-Test and Kruskal-Wallis test) were used to analyze the measurement data. The categorical variables were analyzed by Chi-square test method and Spearman’s rank correlation coefficient was used to test bivariate associations.@*Results@#Liver fibrosis improvement rate after 78 weeks of treatment was 36.53% (80/219) and the progression rate was 23.29% (51/219). The improvement of liver fibrosis was associated to the degree of baseline fibrosis and treatment methods (P < 0.05). The improvement rate of hepatic fibrosis in patients treated with anluohuaxianwan combined with entecavir at baseline F < 3 (54.74%, 52/95) was significantly higher than that in patients treated only with entecavir (33.33%, 16/48), P = 0.016 and the progression rate of hepatic fibrosis (13.68%, 13/95) was lower than that in patients treated alone (18.75%, 9/48), P = 0.466. In patients with baseline F < 3, the proportion of patients with improved and stable liver fibrosis in the combined treatment group (68.1%, 32/47) was higher than that in the treatment group alone (51.7%, 15/29).@*Conclusion@#Combined anluohuaxianwan and entecavir treatment can significantly improve the improvement rate of liver fibrosis in patients with chronic hepatitis B virus infection. Furthermore, it has the tendency to improve the stability rate and reduce the rate of progression of liver fibrosis.
ABSTRACT
Objective The Toxicology study of Tibetan medicine MNXT granules was observed to provide basis for clinical safe medication.Methods The acute toxicity test in mice was conducted with the oral maximum-tolerated dosage,and then toxicity reaction and death situations in mice at 14d after the intragastric administration (ig) one day at 3 times was observed; Long-term toxic test:the does of MNXT granule 13.23 g/kg · d-1,6.667 g/kg· d-1,3.33 g/kg· d-1 (equivalent 100,50,25 times of the clinical dosage) were continuous administered to medicating groups for 30 days,and blank group was given distilled water instead.The rats'behavior,appearance,food intake,water intake,body weight were observed,and the blood,blood biochemical parameters,the main organ coefficient,anatomical,pathological morphology were determined at 30d after administration and 15d after withdrawal.Results The maximum study medication dose of Tibet an medicine MNXT granule was 39 g/kg (equivalent to 300 times the clinical dose) and the mice had not any adverse reaction.Long-term toxicity test:the rats' blood and blood biochemical parameters,the main organ coefficient,anatomical,pathological morphology had not significant differences compared with the blank grou? during the 30d administration and 15d withdrawal.Conclusion Toxicity of the Tibetan medicine MNXT granules was not observed in acute or long-term toxicity test.